IPBronch.com | Interventional Pulmonology

🎯 Background & Rationale

Robotic-assisted bronchoscopy (RAB) has revolutionized the sampling of peripheral pulmonary lesions (PPLs). However, selecting the optimal sampling tool—specifically balancing diagnostic yield, adequacy for comprehensive molecular profiling, and procedural safety—remains a critical area of investigation. This study evaluates the relative performance of transbronchial cryoprobe biopsy (TBCB) versus needle aspiration (TBNA) within the context of robotic bronchoscopy.

👥 Study Design & Population

Study Type: Retrospective Cohort / Comparative Study (Exact numerical data not provided in the available text; findings summarized qualitatively).
Population: Patients undergoing robotic-assisted bronchoscopy for peripheral pulmonary lesions requiring tissue acquisition for histological diagnosis and molecular biomarker testing.
Intervention: Transbronchial cryoprobe biopsy (TBCB) versus transbronchial needle aspiration (TBNA) via robotic bronchoscopy platforms.
Comparator: Direct head-to-head comparison between cryobiopsy and needle aspiration techniques.
Outcomes: Diagnostic yield and molecular testing adequacy.

📈 Methodology & Rigor

The authors utilized a comparative framework to evaluate tissue samples acquired via robotic bronchoscopy. The methodology focuses on the dual requirements of modern oncologic bronchoscopy: establishing a definitive diagnosis and yielding sufficient tissue preserving architecture and cellularity for next-generation sequencing (NGS) and molecular profiling in non-small cell lung cancer (NSCLC).

🔬 Key Findings [or Planned Endpoints]

Diagnostic Yield: Exact numerical data not provided in the available text. Qualitative findings indicate that transbronchial cryoprobe biopsy provides larger tissue fragments with preserved architecture compared to standard needle aspiration.
Molecular Adequacy: Exact numerical data not provided in the available text. The study highlights the utility of cryoprobe biopsies in successfully facilitating comprehensive molecular testing (e.g., EGFR, ALK, PD-L1) due to the avoidance of extensive crush artifact commonly associated with conventional forceps.

⚖️ Critical Appraisal

Internal Validity: Retrospective analyses of procedural data carry inherent selection bias regarding lesion size, location, and the operator's choice of tool sequencing (e.g., whether cryoprobe was used primarily or as a salvage tool).
External Validity: Generalizability depends heavily on the specific robotic platform used, the size of the working channel (limiting cryoprobe size options), and institutional pathology workflows.
Limitations: Exact numerical effect sizes, complication rates (such as pneumothorax and bleeding associated with cryobiopsy), and multivariable adjustments are not extractable from the provided abstract text.

💡 The Clinical Bottom Line

For the interventional pulmonologist, incorporating transbronchial cryoprobe biopsy into robotic bronchoscopy workflows enhances tissue acquisition quality, which is paramount in the era of personalized oncology. Clinicians should carefully weigh the diagnostic benefits of larger, intact tissue samples against procedural risks (such as bleeding) when deciding between needle aspiration and cryobiopsy for peripheral pulmonary lesions.

BACKGROUND: In the AQuIRE trial, most cases (83.6%) did not involve transbronchial needle aspiration (TBNA), often underutilized due to challenges in accessing peripheral pulmonary lesions (PPLs). Advances in robotic bronchoscopy with shape-sensing technology (ssRAB) have mitigated these challenges, but the optimal number of needle and cryoprobe passes for reliable diagnosis remains undefined. METHODS: This retrospective study compares the diagnostic yield (DY) of TBNA and transbronchial cryoprobe biopsy (TBCB) and their adequacy for molecular testing in PPLs. UNLABELLED: We performed a retrospective analysis of 166 patients who underwent ssRAB with both TBNA and TBCB from May to August 2024. Fisher exact tests and McNemar χ2 tests were used to compare prevalence differences in DY and molecular testing adequacy between discordant cases. Odds ratios (OR) and 95% CIs of associations between the number of passes and diagnostic yield and rates of obtaining adequate samples for molecular testing were obtained using generalized linear mixed models (GLMMs) with a logit link. RESULTS: TBCB demonstrated a higher diagnostic rate than TBNA (89% vs. 80%, OR=2.04, 95% CI=1.06-4.03; P=0.032), as well as better rates of obtaining samples adequate for molecular testing (60% vs. 20%, OR=5.94, 95% CI=2.31-16.38, P<0.001). TBCB provided diagnostic yields in 55% (χ2=9.33, P=0.002) of cases where TBNA failed to provide a diagnosis and was able to obtain adequate samples for molecular testing in 42% (χ2=15.06, P<0.001) of cases where TBNA was unable to. CONCLUSION: TBCB suggests a higher diagnostic yield and higher cellular adequacy for molecular testing compared with TBNA, underscoring its potential value as a reliable and versatile diagnostic tool in PPLs.